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Abstract: A reliable and practical multi-method was developed for the quantification of mycotoxins
in plasma, urine, and feces of pigs, and plasma and excreta of broiler chickens using liquid
chromatography–tandem mass spectrometry. The targeted mycotoxins belong to the regulated
groups, i.e., aflatoxins, ochratoxin A and Fusarium mycotoxins, and to two groups of emerging
mycotoxins, i.e., Alternaria mycotoxins and enniatins. In addition, the developed method was
transferred to a LC-high resolution mass spectrometry instrument to qualitatively determine phase I
and II metabolites, for which analytical standards are not always commercially available. Sample
preparation of plasma was simple and generic and was accomplished by precipitation of proteins
alone (pig) or in combination with removal of phospholipids (chicken). A more intensive sample
clean-up of the other matrices was needed and consisted of a pH-dependent liquid–liquid extraction
(LLE) using ethyl acetate (pig urine), methanol/ethyl acetate/formic acid (75/24/1, v/v/v) (pig feces)
or acetonitrile (chicken excreta). For the extraction of pig feces, additionally a combination of LLE
using acetone and filtration of the supernatant on a HybridSPE-phospholipid cartridge was applied.
The LC-MS/MS method was in-house validated according to guidelines defined by the European
and international community. Finally, the multi-methods were successfully applied in a specific
toxicokinetic study and a screening study to monitor the exposure of individual animals.
Keywords: Biomarkers; exposure; LC-MS/MS; LC-HRMS; pig; broiler chicken; multi-mycotoxin
Key Contribution: An LC-MS/MS multi-method was developed, validated and transferred to the
LC-HRMS to determine mycotoxins and their metabolites in plasma, urine and feces of pigs and
plasma and urine of broiler chickens. This method enables the determination of biomarkers for
exposure to mycotoxins in biological samples.
1. Introduction
The worldwide contamination of feed with mycotoxins is of major agro-economic importance.
In addition to crop and feed loss and damage, these mycotoxins can have a large impact on animal
health. Surveys show that mycotoxins occur in more than 70% of the tested feed samples and 38% of
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these samples contain multiple mycotoxins. Co-contamination of several mycotoxins can result in
additive or synergistic effects. Consequently, multi-methods are an asset in mycotoxin analysis [1].
This study focused on the mycotoxins regulated by the European Union [2,3], as well as the
mycotoxins for which legislation is currently lacking but which reveal evident toxicity and high
prevalence in feed [4]. More specifically, aflatoxin B1 (AFB1), ochratoxin A (OTA), fumonisin B1 (FB1),
T2-toxin (T2), zearalenone (ZEN) and deoxynivalenol (DON), as well as enniatins (ENN), beauvericin
(BEA), alternariol (AOH) and tenuazonic acid (TeA) were included.
Traditionally, mycotoxins are determined and regulated at the level of the feed. However, feed
analysis has some major disadvantages. First, the possible presence of mycotoxin hotspots, i.e., local
areas in the feed with a higher concentration, can cause an unequal distribution of mycotoxins
in the feed and make it difficult to obtain a representative sample [5]. Second, analyzing feed
gives no information about the individual exposure. Fluctuations can arise from differences in
food consumption or in absorption, distribution, biotransformation and excretion (ADME) processes
between the animals. Third, the risk associated with exposure can be underestimated because feed
analysis does not include alternative routes of exposure such as dermal and respiratory exposure [6,7].
Fourth, modified or conjugated forms, previously called masked mycotoxins, can convert back to
their free forms and hence contribute to the adverse effects related to mycotoxin exposure. This has
been demonstrated for 3- and 15-acetyldeoxynivalenol (3ADON and 15ADON, respectively) and
DON-3-glucoside (DON3G) in pigs and broiler chickens [8,9]. Therefore, both ADONs and DON3G
can be considered as toxic as DON itself. Detection of these modified forms in feed can be difficult and
is not always possible with conventional methods where the non-modified mycotoxin is determined.
This creates a possible mismatch between the feed contamination level and the exposure of the
animals [10]. Finally, clinical signs of mycotoxin exposure can appear when the contaminated feed
has already been consumed, thus complicating or preventing diagnosis of herd problems associated
with mycotoxins [11].
These issues can be resolved by biomonitoring of the animals and determining the exposure to
mycotoxins in biological matrices with the use of so-called biomarkers of exposure. Biomarkers are
molecules related to the exposure and are often the mycotoxin itself, the in vivo formed metabolites or
interaction products with macromolecules such as nucleic acids or proteins [12,13].
The selected mycotoxins and their phase I and II metabolites or interaction products
(e.g., aflatoxin-guanine) can be measured in several biological matrices. In this study, plasma, urine
and feces of pigs and plasma and excreta of broiler chickens were chosen as biological matrix since
combining these enables studying all the in vivo toxicokinetic parameters and the complete metabolic
profile. Moreover, these matrices can be used to determine the efficacy of mycotoxin detoxifiers
according to the guidelines of the European Food Safety Authority (EFSA) [14]. In addition, they can
be easily applied for the detection of mycotoxins in these animals under field conditions. Especially,
the non-invasive character of urine and feces collection can be of added value when sampling on farm.
Nowadays, state-of-the-art equipment such as liquid chromatography (LC) coupled to a tandem
mass spectrometer (MS/MS) or a high-resolution mass spectrometer (HRMS) have become the
standard in determining mycotoxins in biological matrices. Indeed, several LC-MS/MS multi-methods
(≥2 mycotoxins) have already been developed for the determination of mycotoxins in biological
matrices of pigs and broiler chickens. However, most of these multi-methods are limited to one
group of mycotoxins. Such methods are available for (the metabolites of) DON [9,15–18], ZEN [19,20],
ENNs [21,22], T2 [23–25], AFB1 [26] and TeA [27]. Only few multi-methods combine mycotoxins from
different families. To the best of our knowledge, this is the case for urine [28–33] and plasma [33–35] of
pigs, and plasma [35] of broiler chickens. These multiclass methods are also available for other animal
species such as for fish plasma [36], human plasma and urine [5,37–40], and rat plasma and urine [39].
The methods for urine clean-up often apply immunoaffinity columns or solid phase columns [30–33].
This approach increases the sensitivity but also the cost of analyzing a large number of samples and it
limits the number of analytes that can be detected. To avoid these limitations, the dilute and shoot
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approach without further pre-treatment is frequently used [5,37,39,40]. However, this method demands
careful optimization of the dilution factor, and often matrix effects and interfering matrix peaks are
observed, which might decrease the sensitivity. Therefore, liquid–liquid extractions (LLE) are preferred
as urine sample preparation because they are easy to perform in large quantity and enough sensitivity
can be obtained. The developed plasma methods by Brezina et al. [41] and De Baere et al. [35] use
OASIS HLB columns that require conditioning before use, limiting the number of samples that can be
processed in a period of time. To increase the possible number of samples processed, LLE and protein
precipitation are preferred. This study therefore aimed to develop a practical, fast and cost-efficient
multi-method for analysis of plasma and urine of pigs and plasma of chickens, using LLE and protein
precipitation, avoiding the use of affinity/solid phase columns.
Multi-methods are to the best of our knowledge currently not available for pig feces and excreta of
broiler chickens. This might be due to high matrix complexity and the diversity of the physicochemical
characteristics of the mycotoxins. Hence, the aim of this study was also to address these difficulties
and to develop a multi-method in these highly complex matrices.
LC-HRMS is especially interesting to elucidate and determine phase I and II metabolites and
interaction products for which analytical standards are not easily available. Especially, since phase
II metabolites might be the most appropriate biomarkers for some mycotoxins due to the extensive
biotransformation by these pathways. The glucuronidated and sulfated metabolites of DON and ZEN,
as well as the metabolites formed after hepatic biotransformation of ENNB and B1 have already been
determined using LC-HRMS [9,20,22,42]. However, to our knowledge, these metabolites of several
toxins belonging to multiple classes have never been determined in a single chromatographic run
using LC-HRMS.
Thus, the combination of LC-MS/MS and LC-HRMS enables not only determining mycotoxins
with an appropriate sensitivity in the lower ng/mL or ng/g range but also detecting a broad range of
mycotoxins, i.e., the mycotoxins and metabolites for which standards are readily available as well as
other phase I and II metabolites and interaction products. This is especially interesting when assessing
the most appropriate biomarker for exposure.
Therefore, the aim of this study was to develop and validate multi-methods using LC-MS/MS
to determine relevant mycotoxins in biological matrices of pigs and broiler chickens. In addition,
the LC-MS/MS method was transferred to LC-HRMS to determine mycotoxins for which analytical
standards are not always commercially available. It is important to consider the main challenges
including the high complexity of the matrix, the large range of different physicochemical characteristics
of the mycotoxins and the need for a method with an appropriate sensitivity (in the lower ng/mL or
ng/g range), so that they can be used not only for specific toxicokinetic studies but also for screening
studies to monitor the exposure of individual animals.
2. Results and Discussion
2.1. Method Development
2.1.1. Sample Preparation and Extraction
Three requirements were prioritized in the development of adequate sample pre-treatments for
the different matrices. First, the sample preparation should be simple and practical, thereby enabling
analysis of a large quantity of samples in a time and cost efficient way. Second, the sample preparation
should be as generic as possible, to allow the extraction of the 24 mycotoxins including some relevant
metabolites, which was a real challenge taking into account the various physicochemical properties of
the different classes of mycotoxins. Third, the method should be sensitive and, therefore, an LOQ of
1 ng/mL of ng/g was aimed for all analytes in all matrices.
Initially, all methods started from the most generic and simple sample preparation:
deproteinization with an organic solvent. However, due to high matrix complexity and the large
variety in physicochemical characteristics of the different mycotoxins more complex methods were
Toxins 2019, 11, 171 4 of 30
needed for urine, feces and excreta. A summary of the final protocols can be found in the flowchart
below (Figure 1).
Pig and Chicken Plasma
Method development was started with the optimization of the extraction of the analytes
of interest from pig and chicken plasma. Proteins and phospholipids are often removed from
plasma samples before analysis on LC-MS/MS equipment to prevent clotting and contamination
of the equipment. Deproteinization can be accomplished using organic solvents, such as MeOH
and ACN. The elimination of phospholipids could be obtained using an Oasis Ostro®-plate or
HybridSPE®-phospholipid 30 mg/1 mL solid-phase extraction (SPE) tubes. The use of the Ostro®-plate
required the addition of 0.1% formic acid. Therefore, 0.1% formic acid was added to ACN and MeOH.
For pig plasma, deproteinization with 0.1% formic acid in MeOH and 0.1% formic acid in ACN
were tested in triplicate on spiked pig plasma samples (analyte concentration: 10 ng/mL). In this
study, ACN was preferred as deproteinization solvent for pig plasma, compared to MeOH, since it
gave a clearer supernatant after centrifugation. This is in accordance with previous studies where
deproteinization with ACN was successfully applied to detect mycotoxins in pig plasma [20,34].
Plasma of broiler chickens contains more phospholipids compared to pigs [43]. Therefore,
an additional removal of the phospholipids was necessary to obtain clear samples and to prevent
clogging of tubings of the LC-MS/MS and LC-HRMS instruments during routine sample analysis.
Spiked broiler chicken plasma samples (analyte concentration: 10 ng/mL) were extracted using the
Oasis Ostro®-plate or the hybrideSPE® phospholipid SPE tubes (n = 3 per protocol). As can be seen in
Figure 2, the use of SPE tubes resulted in a lower peak area, especially for ENNs, BEA, TEA, AME
and AOH. Consequently, for broiler chicken plasma, deproteinization with ACN and 0.1% formic acid
was combined with the Oasis Ostro®-plate to obtain the best results. This combination was already
successfully applied to detect mycotoxins in chicken plasma by our group [44].
Pig Urine
Since methanol and ACN are mixable with urine, it was not possible to use the same method
for urine as for plasma. The use of immunoaffinity columns is avoided due to the high cost. Dilute
and shoot methods were eliminated to avoid matrix effects. Therefore, LLE was used to extract the
mycotoxins from urine. The main parameters affecting the extraction of all components were optimized:
type of extraction solvent, pH, solvent volume and extraction time. During initial experiments, ethyl
acetate was evaluated as extraction solvent at neutral pH as in literature extraction of mycotoxins from
human urine with this solvent can be found [5,28]. Next, the pH of extraction was optimized using
urine spiked at analyte concentrations of 10 ng/mL (n = 2 per protocol): acidic (pH 2), neutral (pH 8)
and basic (pH 10) extraction conditions were evaluated. Most components showed good extraction at
neutral pH (see Figure 3); only for TeA, HT2 and OTA neutral pH showed insufficient results. For these
components, significantly higher peak areas were observed at pH 2. This can be explained by the
pKa-values of these components. The pKa of TeA (4.5 ± 1) and OTA (3.2 ± 0.1) [45,46] indicate that
these components are weak acids and at pH 2 all these components will be neutral and can thus easily
be extracted. The pKa values and chemical formulas of the other toxins can be found in Supplementary
Table S12. As a result, it was decided to perform two extraction protocols for pig urine, i.e., one in
acidic medium (pH 2, tube 1) and another in neutral medium (pH 7, tube 2). Since the same internal
standard was used for TeA as for AME and AOH and these components were also detected in acidic
medium, they were also added to the acidic protocol. Finally, the volume of ethyl acetate and the
extraction time were also optimized. Different volumes (1.5, 3, 5, and 7.5 mL) and different extraction
times (15, 30, 45, and 60 min) were tested. It was found that extraction was optimal using a solvent
volume of 3 mL and an extraction time of 15 min (results not shown). The combination of both extracts
into one vial was not possible since DOM1 and ADON were no longer recovered.
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Chicken Excreta
For the excreta of broiler chickens, the same solvents as used for extraction of urine and
deproteinization of plasma were evaluated: ACN, MeOH and ethyl acetate. The excreta samples
were spiked at an analyte concentration of 10 ng/g (n = 3 per protocol). MeOH extraction of broiler
chicken excreta did not contain all the metabolites of ZEN. In addition, the peak areas of the measured
metabolites of ZEN and DON and AOH/AME were much lower. Next, the chromatograms after
extraction with ethyl acetate and ACN were compared. The ethyl acetate extract showed a lower S/N
ratio for ZEN and its metabolites. Moreover, the peak areas for the ENNs, AFB1 and DON family were
much higher after extraction with ACN compared to ethyl acetate (Figure 4). Therefore, ACN was
chosen as optimal extraction solvent. However, to improve the recovery, the influence of the addition
of salts (MgSO4 and Na2SO4), acid (HCl), base (NaOH) and water on the extraction recovery was also
evaluated. The extraction recovery of TeA and OTA increased by a factor 100 by adding HCl, whereas
for all the other components extraction with ACN alone showed the highest recovery. Therefore, it was
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decided to perform the extraction of chicken excreta twice: with and without HCl (only for TeA and
OTA). The final protocol for broiler chicken excreta used 1.5 mL of ACN as an extraction solvent.
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Pig Feces
The extraction of mycotoxins from pig feces was initially evaluated using the same solvents as
for the optimization of chicken excreta: MeOH, ACN, and ethyl acetate. However, these solvents did
not give satisfactory results in recovery and the extracts were not sufficiently clean to inject into the
instrument. Therefore, other extraction solvents (acetone, diethyl ether) were also evaluated, but the
recovery of the mycotoxins was still insufficient. This could be explained by the complexity of the
matrix. This challenge was solved by testing different combination of solvents and the combination
of the different solvents with SPE columns. This led to a double extraction procedure. The first
extraction was a liquid extraction using MeOH/ethyl acetate/formic acid (75/24/1; v/v) to extract
OTA, TeA, AME and AOH. The second protocol to extract the other mycotoxins was a combination of
a liquid extraction with acetone and a solid phase extraction with a HybridSPE-phospholipid column.
All extraction procedures were tested in triplicate at analyte concentrations of 10 ng/g.
Both feces and excreta extraction required the use of a filtration step using the Millex®-LG filter
unit (0.2 µm) to obtain samples that were sufficiently clean to inject on the equipment.
For all matrices, the dried extract was reconstituted in 250 µL (or 150 µL for chicken plasma)
of MeOH/water (85/15; v/v). The combination of water and MeOH was crucial to redissolve all
mycotoxins with their various physicochemical characteristics.
2.1.2. Optimization of LC-MS/MS and HRMS Parameters
Four different reversed phase columns (Hypersil Gold 50 mm × 2.1 mm, dp: 1.9, Thermo Scientific,
Breda, The Netherlands; Zorbax Eclipse C18 50 mm × 2.1 mm, dp: 1.8, Agilent, Sint-Katelijne-Waver,
Belgium; Acquity BEH-C18 50 mm × 2.1 mm, dp: 1.7, Waters, Milford, MA, USA; and Acquity HSS-T3
100 mm × 2.1 mm, dp: 1.8, Waters, Milford, MA, USA) were tested to achieve chromatographic
separation of the selected mycotoxins. The best separation of all components was obtained on the
HSS-T3 column.
The multi-methods were developed with two subsequent analytical runs, i.e., ESI+ and ESI−
mode respectively. This was necessary to be able to detect all the mycotoxins with sufficient sensitivity
without increasing the run time. Therefore, the mobile phases for each ionization mode were optimized
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separately. In the literature, the most common mobile phases for mycotoxin detection consist of water
and an organic solvent (such as ACN or MeOH). These solvents are often combined with mobile phase
modifiers such as volatile acids (formic acid and acetic acid) and ammonium formate or ammonium
acetate [34,35]. Different combinations of these solvents and modifiers were evaluated to identify the
optimal combination for each ionization mode.
In ESI− mode, ZEN, AZEL, BZEL, AZAL, BZAL, ZAN, TeA, AOH and AME were determined.
Baseline separation among ZAN, AZEL, and BZEL as well as between AZAL and BZAL was achieved
using water (MP A) and ACN (MP B) as mobile phases [20]. The use of mobile phase with a pH close to
neutral led to an impaired peak shape for TeA [47]. The peak shape was optimal when using 1% acetic
acid. Therefore, 1% acetic acid in water and 1% acetic acid in ACN were chosen as final mobile phases,
since this combination gave satisfactory results for all analytes. Figure 5a shows the chromatographic
separation of the mycotoxins in ESI− mode with the optimized parameters as described here.
DON, DOM-1, 3-ADON, 15-ADON, T2, HT2, T2G, OTA, AFB1, AFM1, FB1, ENNA, ENNA1,
ENNB, ENNB1 and BEA were determined in ESI+ mode. Taking into account all analytes,
the combination of water (MP A) and MeOH (MP B) was most suitable [34]. These mobile phases
were further optimized using ammonium formate and formic acid to evaluate the formation of
ammonium adducts (M + [NH4+]). These adducts are generally easier to fragment than sodium
adducts, thus enhancing the sensitivity of the method. The final combination of mobile phases was
10 mM ammonium formate and 0.3% formic acid in water (MP A) and in methanol (MP B). Figure 5b,c
shows the chromatographic separation of the mycotoxins in ESI+ mode with the optimized parameters
as described here.
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AME and AOH; [13C18]-Zearalenone for ZEN, AZAL, BZAL, AZEL, BZEL and ZAN; and [15N3]-
Enniatin B for ENNA, ENNA1, ENNB, ENNB1 and BEA. Hence, an optimal correction for matrix 
Figure 5. (a) LC- S/MS chromatogram showing the separation of tenuazonic acid (TeA,
6.16 min), alternariol (AOH, 6.45 min), α-zearalanol (AZAL, 7.34 min), α-zearalenol (AZEL,
7.47 min), β-zearalanol (BZAL, 6.73 min), β-zearalenol (BZEL, 6.84 min), zearalanone (ZAN,
8.38 min), zearalenone (ZEN, 8.47 min) and alternariol-monomethyl ether (AME, 8.52 min) at a
concentration of 10 ng/mL in broiler chicken plasma; (b) LC-MS/MS c romatogram showing the
separation of deoxynivalenol (DON, 4.37 min), de-epoxy-de xynivalenol (DOM1, 4.71 min), 3/15-
acet l-deoxynivalenol (3/15-ADON, 5.02 min), aflatoxin (AFM1, 5.20 min), aflatoxin (AFB1,
5.73), HT2-toxin (HT2, 7.01 min), T2-glucoside (T2G, 7.08 min), T2 toxin (T2, 8.27 min), ochratoxin
A(OTA , 9.28 min), beauvericin (BEA) and the enniatins (ENNA, A1, and B1) in broiler chicken plasma
at a concentration of 10 ng/mL; and (c) enlargement of (b): LC-MS/MS chromatogram showing t e
se ar ti of BEA and the enniatins (ENNA, A1, B and 1) i broiler chicken plasma at a concentr ion
of 10 g/mL.
Since an isotopically labeled IS for each single mycot xin is too expensive and not
commercially availabl , an IS labeled with [13C] or [15N] was used for each group of mycotoxins.
[13C15]-deoxynivalenol w used as IS for DON, DOM-1 and 3/15ADON; [13C17]-Aflatoxin B1 for
B1 and AFM1; [13C20]-Ochratoxin A for OTA; [13C34]-Fumonisin B1 for FB1; [13C615N]-Tenuazonic
acid for Te , AME and AOH; [13C18]-Zearalenone for ZEN, AZAL, BZAL, AZEL, BZEL and ZAN;
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and [15N3]-Enniatin B for ENNA, ENNA1, ENNB, ENNB1 and BEA. Hence, an optimal correction
for matrix effects and losses during sample preparation was obtained, which was confirmed during
method validation (see Table 2, Tables S6–S9, and Results Section for accuracy and precision).
Data acquisition on the high-resolution mass spectrometer (HRMS) was done in the positive or
negative ESI resolution mode, using the MSE continuum scan function. The results were processed
using the Unify version 1.8 software (Milford, MA, USA) to determine the phase I and II metabolite,
for which no commercial analytical standards were available.
Metabolites known in the literature were added to the accurate mass—MSe screening method
and additionally a pathway profiling MSE processing method (the chemical formulas and theoretical
accurate masses were added) with additional adducts and transformations was made. Peaks were
identified based on the found accurate mass in the low energy spectrum and the product ions generated
in the high energy spectrum. An additional confirmation criterion was the observed profile of peak
areas versus time, seen in the samples obtained during the toxicokinetic study. An example of an
extracted ion chromatogram of a glucuronidated metabolite of ZEN and the corresponding low energy
and high energy spectra, which was detected in a plasma sample of a pig administered an intra-gastric
bolus of ZEN (3 mg/kg bw), is shown in Figure 6.
The Unify version 1.8. software (Waters, Milford, MA, USA) detected two peaks with the
exact mass of ZEN-glucuronide [m/z 494.1788]. However, only the MS/MS spectrum of the second
peak (4.68 min) showed the product ions [m/z 317 and 175] of ZEN-glucuronide as defined in the
literature [19]. The first fragment ion (m/z = 317), corresponds with the loss of glucuronic acid
(176 amu) and the second at m/z = 175 results from the loss of the aglycone from the quasimolecular
ion [48]. The data of the first peak can be found in Figure S1.
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Figure 6. (A) LC high-resolution extracted mass chromatogram of a plasma sample that was taken 
from a pig that received an intra-gastric bolus of zearalenone (ZEN) (3 mg/kg bw); the following mass-
to-charge (m/z) values, corresponding to the theoretical exact mass of the deprotonated molecular ions 
[M − H]−, were extracted from the total ion chromatogram using Unify 1.8 software: ZEN-glucuronide: 
[m/z 493.1788]. (B) In the low energy MS/MS spectrum, this mass was confirmed as m/z-value 
493.17121 (target mass error = 10 ppm). (C) In the high energy MS/MS spectrum, the corresponding 
product ions at m/z 317.13877 and 175.04015 (target mass error = 10 ppm) are shown. 
2.2. Method Validation 
The most optimal extraction protocol for plasma, urine and feces of pigs and plasma of broiler 
chickens was not validated for fumonisins due to low recovery. Therefore, it was decided to only 
validate fumonisin B2 in broiler chicken excreta, hence in this matrix 25 mycotoxins were validated. 
The correlation coefficient (r) and the goodness-of-fit (g) are shown in Table 1 as an average ± 
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curves matched a linear calibration model with a 1/x weighing factor, except for the ENNs and BEA. 
These components show a quadratic 1/x model. Linearity results of each component separately for 
pig plasma are shown in Table 1. 
Table 1. Validation results for linearity (linear range, correlation coefficient (r) and goodness-of-fit 
coefficient (g)) and limit of quantification (LOQ) of 24 mycotoxins in pig plasma. 
Analyte 
Linearity (n = 3 Different Days) 
LOQ (ng/mL) 
Linear Range (ng/mL) r ± SD g (%) ± SD 
ZEN 1–200 0.996 ± 0.003 12.9 ± 3.8 1.0 
AZEL 1–200 0.995 ± 0.002 15.0 ± 1.2 1.0 
AZAL 1–200 0.995± 0.003 15.2 ± 3.6 1.0 
BZAL 1–200 0.996 ± 0.001 10.7 ± 2.0 1.0 
BZEL 1–200 0.996 ± 0.002 14.9 ± 3.7 1.0 
ZAN 1–200 0.997 ± 0.001 16.3 ± 3.1 1.0 
TEA 1–200 0.998 ± 0.001 12.0 ± 4.9 1.0 
AOH 1–200 0.997 ± 0.002 12.9 ± 5.2 1.0 
AME 1–200 0.996± 0.004 13.1± 5.1 1.0 
DON 1–200 0.998 ± 0.002 13.9 ± 4.4 1.0 
DOM-1 1–200 0.997 ± 0.003 16.9 ± 2.5 1.0 
3/15 ADON 1–200 0.998 ± 0.001 9.3 ± 3.1 1.0 
T2 1–200 0.998 ± 0.001 9.9 ± 1.6 1.0 
HT2 1–100 0.993 ± 0.002 17.5 ± 2.8 1.0 
T2G 2–200 0.995 ± 0.003 14.4 ± 1.2 2.0 
AFB1 1–200 0.996 ± 0.002 12.7 ± 2.8 1.0 
Figure 6. (A) LC high-resolution extracted ass chromatogram of a plasma sample that was taken
from a pig that received an intra-gastric bolus of zearalenone (ZEN) (3 mg/kg bw); the following
mass-to-charge (m/z) values, corresponding to the theoretical exact mass of the deprotonated
molecular ions [M − H]−, were extracted from the total ion chromatogram using Unify 1.8 software:
ZEN-glucuronide: [m/z 493.1788]. (B) In the low energy MS/MS spectrum, this mass was confirmed
as m/z-value 493.17121 (target mass error = 10 ppm). (C) In the high energy MS/MS spectrum,
the corresponding product ions at m/z 317.13877 and 175.04015 (target mass error = 10 ppm) are shown.
2.2. Method Validation
The most optimal extraction protocol for plasma, urine and feces of pigs and plasma of broiler
chickens was not validated f r fumonisins due to low recovery. Theref re, it was deci ed to only
validate fumonisin B2 in broil r chicken excreta, hence in this matrix 25 mycotoxins were v lidated.
The correlation c effici nt (r) and the g odness-of-fit (g) are shown in Table 1 as an average ±
standard deviation of three curves made across three different analysis days. The linearity results for
the other matrices can be found in Tables S2–S5. They ranged for pig plasma from 0.993 to 0.998 (r) and
9.0% to 17.5% (g); for pig urine from 0.995 to 0.999 (r) and 3.5% to 17.0% (g); for pig feces from 0.993 to
0.999 (r) and 7.1% to 18.7% (g); for chicken plasma from 0.994 to 0.999 (r) and 5.9% to 17.7% (g); and for
chicken excreta from 0.995 to 0.999 (r) and 5.1% to 16.80% (g). Most of the calibration curves matched a
linear calibration model with a 1/x weighing factor, except for the ENNs and BEA. These components
show a quadratic 1/x model. Linearity results of each component separately for pig plasma are shown
in Table 1.
Table 1. Validation results for linearity (linear range, correlation coefficient (r) and goodness-of-fit
coefficient (g)) and limit of quantification (LOQ) of 24 mycotoxins in pig plasma.
Analyte
Linearity (n = 3 Different Days)
LOQ (ng/mL)Linear Range
(ng/mL) r ± SD g (%) ± SD
ZEN 1–200 0.996 ± 0.003 12.9 ± 3.8 1.0
AZEL 1–200 0.995 ± 0.002 15.0 ± 1.2 1.0
AZAL 1–200 0.995± 0.003 15.2 ± 3.6 1.0
BZAL 1–200 0.996 ± 0.001 10.7 ± 2.0 1.0
BZEL 1–200 0.996 ± 0.002 14.9 ± 3.7 1.0
ZAN 1–200 0.997 ± 0.001 16.3 ± 3.1 1.0
TEA 1–200 0.998 ± 0.001 12.0 ± 4.9 1.0
AOH 1–200 0.997 ± 0.002 12.9 ± 5.2 1.0
AME 1–200 0.996± 0.004 13.1± 5.1 1.0
DON 1–200 0.998 ± 0.002 13.9 ± 4.4 1.0
DOM-1 1–200 0.997 ± 0.003 16.9 ± 2.5 1.0
3/15 ADON 1–200 0.998 ± 0.001 9.3 ± 3.1 1.0
T2 1–200 0.998 ± 0.001 9.9 ± 1.6 1.0
HT2 1–100 0.993 ± 0.002 17.5 ± 2.8 1.0
T2G 2–200 0.995 ± 0.003 14.4 ± 1.2 2.0
AFB1 1–200 0.996 ± 0.002 12.7 ± 2.8 1.0
AFM1 1–200 0.997 ± 0.002 13.8 ± 5.6 1.0
OTA 1–200 0.993 ±0.004 9.3 ± 2.9 1.0
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Analyte
Linearity (n = 3 Different Days)
LOQ (ng/mL)Linear Range
(ng/mL) r ± SD g (%) ± SD
ENNA1 1–200 0.998 ± 0.001 9.0 ± 0.9 1.0
ENNA 1–50 0.995 ± 0.003 13.9 ± 3.2 1.0
ENNB 1–100 0.993 ± 0.002 9.3 ± 1.2 1.0
ENNB1 1–100 0.998 ± 0.001 15.9 ± 2.3 1.0
BEA 1–100 0.998 ± 0.000 16.6 ± 4.5 1.0
Note: SD, standard deviation; acceptance criteria: r ≥ 0.990 and g ≤ 20.
The LOQ that was aimed for during method development was 1 ng/mL or ng/g. This could be
obtained for the majority of the components in the different matrices, with the following exceptions:
DOM1 (4 ng/mL) and T2G (2 ng/mL) in pig urine; T2G (2 and 5 ng/mL) in pig and broiler chicken
plasma; and T2G (2 ng/g), HT2 (4 ng/g) and FB2 (10 ng/g) in broiler chicken excreta. In pig feces,
the LOQ for ZEN, AZAL, AOH, DON, DOM-1, HT2 and T2G was established at 5 ng/g.
No peaks were detected at the retention time zone of the analytes of interest in the solvent sample
that was injected after the highest calibrator sample, thus demonstrating the absence of carry over.
Moreover, for none of the components a signal was observed at the elution zone of the analytes of
interest in a blank matrix sample. This indicates a good specificity of the method.
The results of the within-day and between-day precision and accuracy met the specifications for
all mycotoxins and matrices. The results can be found in Table 2 for pig plasma and Tables S6–S9 for
the other matrices.
The results for matrix effects (signal enhancement and suppression) and extraction recovery are
shown in the Tables S10 and S11. Most components gave acceptable results (range 60–140%). However,
for some components, matrix effects were more pronounced and recovery was rather low. However,
for all mycotoxins, an adequate internal standard and matrix-matched calibration curves were used,
resulting in validation results for accuracy and precision matching the acceptance criteria.
The validation results for the other matrices can be found in Tables S6–S9.
This resulted in a fully validated quantitative targeted LC-MS/MS method and additionally
a qualitative untargeted LC-HRMS method. Both methods together enable not only determining
mycotoxins with good sensitivity but also targeting a broad range of mycotoxins and their metabolites,
not limited by the commercial availability of standards. This approach makes is possible to determine
24 mycotoxins and their relevant metabolites in easily obtainable biological matrices (plasma, urine
and feces) of pigs and broiler chickens. This is the first time that a paper covers such a broad range
of matrices and mycotoxins with a simple and practical sample preparation. This leads to a general
applicable method that can be applied in, among others, in vivo toxicokinetic studies and screening
studies to investigate the exposure of individual animals to mycotoxins, as shown in Section 2.3.
2.3. Biological Samples: Toxicokinetic Study
2.3.1. Pigs
In the pig plasma samples, low concentrations (1–15 ng/mL) of DON and ZEN were found
using LC-MS/MS analysis. The plasma concentration–time curves for these components are shown in
Figure S2. However, analysis of the samples using the LC-HRMS instrument showed that DON-GlcA
and ZEN-GlcA are better biomarkers for exposure as their observed peak areas are much higher
than those of the respective parent components DON and ZEN [9,20]. Since no DON-GlcA and
ZEN-GlcA standards were available at our laboratory, these components were tentatively identified
using the LC-HRMS multi-method. DON-GlcA and ZEN-GlcA plasma response–time curves are
shown in Figure 7. The highest response for ZEN-GlcA was achieved at 30 min and for DON-GlcA at
4 h post-administration.
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Table 2. Results of the within-day and between-day precision and accuracy experiments for 24 mycotoxins in pig plasma.














Precision Accuracy Precision Accuracy Precision Accuracy Precision Accuracy Precision Accuracy Precision Accuracy
(RSD %) (%) (RSD %) (%) (RSD %) (%) (RSD %) (%) (RSD %) (%) (RSD %) (%)
ZEN 12.1 6.5 7.3 1 5.4 −1.5 13.4 2.7 7.5 2.4 5.7 −2.2
AZEL 6.5 19.7 13 2.3 7.4 6.6 35.4 −5.3 10.9 −0.7 11.6 1.5
AZAL 17.4 −14.5 7.7 −1.4 4.4 −0.4 20.9 −3.3 8.2 −5.2 8.1 −4.9
BZAL 5.2 7 3.5 8.2 2.9 8.9 9.3 6.2 3.9 6.6 10.7 4.2
BZEL 13.0 −9.2 5.1 −1.8 6.1 −2.4 15.9 −1.8 8.1 −4.9 6.6 −5.3
ZAN 11.7 −40.5 3.9 8.8 4.6 3.0 21.5 −32.4 3.6 9.8 7.1 0.4
TEA 2.8 19.0 3.2 8.2 3.6 4.5 10.7 18.2 3.4 8.7 5.8 4.8
AOH 17.6 −32.2 3.5 8.6 3.8 −0.4 26.9 −20.8 4.5 9.5 5.3 −3.1
AME 14.1 10.1 7.7 2.4 4.8 −12.3 18.7 −5.3 7.0 4.8 5.9 −11.9
DON 24.9 −8.0 6.9 1.0 5.6 −5.7 22.3 4.4 10.0 2.3 8 −4.6
DOM-1 17.5 −0.4 15.0 −3.3 5.9 −6.9 14.7 −2.0 14 −2.7 7.9 −7.3
3/15 ADON 15.6 7.5 5.2 5.2 6.4 −3.5 16.4 10.9 5.4 6.9 8.6 −3.5
T2 15.4 3.3 1.6 7.7 2.7 8.4 12.7 3.7 1.5 8.1 6.2 5.0
HT2 21.1 −29.8 6.5 −14.0 9.9 5.8 30.5 −21.4 10.0 −11.5 5.7 2.1
T2G 10.8 −3.8 7.8 6.9 7.0 1.3 23.8 −2.6 9.5 4.1 13.8 6.6
AFB1 13.1 −14.3 3.0 3.9 4.9 −2.0 16.4 −16.9 3.6 4.5 6.3 −2.8
AFM1 11.2 −38.8 10.6 −19.5 8.8 −15.6 28.0 −28.5 18.8 −7.1 20.2 −5.4
OTA 7.5 13.4 8.7 −13.3 4.5 −12.3 14.4 2.5 7.2 −12.5 9.2 −8.0
ENN A1 15.7 −11.3 12.6 −3.7 6.7 1.8 14.6 −2.3 10.8 −0.8 9.6 −0.9
ENNA 19.4 −1.0 9.4 −14.1 11.7 −14.7 41.7 −11.2 13.8 −6.8 13.5 −5.6
ENNB 16.7 −0.1 11.8 9.6 2.6 9.4 16.8 −1.4 13.9 −1.3 6.6 4.1
ENNB1 7.6 16.1 3.9 −0.1 3.5 −3.9 31.8 1.6 8.7 5.5 3.2 −3.2
BEA 13.3 −2.9 3.2 6.9 3.2 7.4 29.7 −6.3 2.3 7.2 11.9 8.5
Note: The acceptance criteria: Accuracy, ≤1 ng/mL: −50% to +20%; 1–10 ng/mL: −30% to +10%; ≥10ng/mL: −20% to +10%. Within-day precision: RSD% < RSDmax with RSDmax for
≥1 to <10 ng/mL: <25% and ≥10 to <100 ng/mL: <15%. Between-day precision: the RSD% < RSDmax with RSDmax 22.6%, 32% and 45% for the respective concentrations of 100 ng/mL,
10 ng/mL and 1 ng/mL, respectively.






Figure 7. (A) HRMS response–time curve of deoxynivalenol-glucuronide (DON-GlcA) in plasma after 
intra-gastric administration of deoxynivalenol (DON, 36 µg/kg bw) to pigs (n = 8). The mean ratio of 
the HRMS peak areas of DON-GlcA/13C15-DON + SD is shown. (B) HRMS response–time curve of 
zearalenone-glucuronide (ZEN-GlcA) in plasma after intra-gastric administration of zearalenone 
(ZEN, 3 mg/kg bw) to pigs (n = 8). The mean ratio of the HRMS peak areas of ZEN-GlcA/13C18-ZEN + 
SD is shown. 
In pig feces, no traces of DON were observed. This can be explained by the complete absorption 
and fast elimination of DON in urine, while only 1–3% of the administered dose is reported to be 
excreted via feces [16]. The concentration–time profiles of ZEN and its phase I metabolites in feces 
showed maximum levels from the first 12 h after exposure onwards (Figure 8). The highest amounts 
were excreted during 12–24 h. This is in line with the observations of Binder et al., who found the 
highest amounts of ZEN and metabolites were excreted during 24–48 h [19]. 
i r . ( ) r s s ti r f i l l- l r i ( - l ) i l s ft r
i tr - stric i istr ti of deoxynivalenol ( , 36 µg/ ) t i s ( ). e e r ti f
t e S peak areas of DON-GlcA/13 15-DON + SD is s . ( ) S res se–ti e c r e f
zearalenone-glucuronide (ZEN-GlcA) in plasma after intra-gastric administration of zearalenone (ZEN,
3 mg/kg bw) to pigs (n = 8). The mean ratio of the HRMS peak areas of ZEN-GlcA/13C18-ZEN + SD
is shown.
In pig feces, no traces of DON were observed. This can be explained by the complete absorption
and fast elimination of DON in urine, while only 1–3% of the administered dose is reported to be
excreted via feces [16]. The concentration–time profiles of ZEN and its phase I metabolites in feces
showed maximum levels from the first 12 h after exposure onwards (Figure 8). The highest amounts
were excreted during 12–24 h. This is in line with the observations of Binder et al., who found the
highest amounts of ZEN and metabolites were excreted during 24–48 h [19].
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Figure 8. (A) Concentration–time curve of zearalenone (ZEN) in feces after intra-gastric 
administration of ZEN (3 mg/kg bw) to pigs (n = 8). The mean + SD is shown. (B) Concentration–time 
curves of α-zearalenol (AZEL) in feces after intra-gastric administration of ZEN (3 mg/kg bw) to pigs 
(n = 8). The mean + SD is shown. (C) Concentration–time curve of β-zearalenol (BZEL) in feces after 
intra-gastric administration of ZEN (3 mg/kg bw) to pigs (n = 8). The mean + SD is shown. (D) 
Concentration–time curve zearalanone (ZAN) in feces after intra-gastric administration of ZEN (3 
mg/kg bw) to pigs (n = 8). The mean + SD is shown.  
In pig urine, DON, ZEN and ZEN-GlcA were detected. The maximum concentrations were 
achieved after 4–8 h for ZEN, ZEN-GlcA and DON. Nagl et al. also demonstrated a fast elimination 
of DON in urine with a maximum concentration in the first 4 h. DON showed to be the most 
important urinary metabolite [16]. Binder et al. also detected ZEN and ZEN-GlcA in pig urine after 
oral administration of ZEN, with ZEN-GlcA as the major metabolite. In this study, the response ratio 
of ZEN-GlcA/IS was also much higher than the area ratio of ZEN/IS, indicating ZEN-GlcA as a major 
metabolite [19]. The concentration (or HRMS response)–time curves of these molecules are depicted 
in Figure 9. 
In all feces and urine samples, low concentrations (or HRMS response areas) were observed at 
the time of administration due to the presence of low levels DON and ZEN in the feed. In urine, this 
concentration was negligible, especially when compared to the concentration after administration. In 
feces, the effect of the administration was only seen after 10 h. Twelve hours fasting before 
administration was not enough to eliminate the concentration of mycotoxins in feces after long-term 
exposure in this study. However, blank samples were obtained in previous studies, as shown in 
Figure S3. 
Figure 8. (A) Conce tration–time curve of zearalenone (ZEN) in feces after intra-gastric administra ion
of ZEN (3 mg/kg bw) to pigs (n = 8). The mean + SD is shown. (B) Concentratio –time curv s
of α-zearalenol (AZEL) in feces after intra-gastric administration of ZEN (3 mg/kg ) t pigs
(n = 8). The mean + SD i shown. ( ) Co centration–time curve of β-z aralenol (BZEL) in feces
after intra-g stric administration of ZEN (3 mg/kg bw) to pigs (n = 8). The mean + SD is shown.
(D) Concentration–time curve zearalanone (ZAN) in feces after intra-gastric administration of ZEN
(3 mg/kg bw) to pigs (n = 8). The mean + SD is shown.
In pig urine, DON, ZEN and ZEN-GlcA were detected. The maximum concentrations were
achieved after 4–8 h for ZEN, ZEN-GlcA and DON. Nagl et al. also demonstrated a fast elimination of
DON in urine with a maximum concentration in the first 4 h. DON showed to be the most important
urinary metabolite [16]. Binder et al. also detected ZEN and ZEN-GlcA in pig urine after oral
administration of ZEN, with ZEN-GlcA as the major metabolite. In this study, the response ratio of
ZEN-GlcA/IS was also much higher than the area ratio of ZEN/IS, indicating ZEN-GlcA as a major
metabolite [19]. The concentration (or HRMS response)–time curves of these molecules are depicted in
Figure 9.
In all feces and urine samples, low concentrations (or HRMS response areas) were observed at
the time of administration due to the presence of low levels DON and ZEN in the feed. In urine,
this concentration was negligible, especially when compared to the concentration after administration.
In feces, the effect of the administration was only seen after 10 h. Twelve hours fasting before
administration was not enough to eliminate the concentration of mycotoxins in feces after long-term
exposure in this study. However, blank samples were obtained in previous studies, as shown in
Figure S3.








Figure 9. (A) Concentration–time curves of deoxynivalenol (DON) in urine after intra-gastric 
administration of DON (36 µg/kg bw) to pigs (n = 8). The mean + SD is shown (B) Concentration–time 
curves of zearalenone (ZEN) in urine after intra-gastric administration of ZEN (3 mg/kg bw) to pigs 
(n = 8). The mean + SD is shown. (C) The HRMS response–time curves of zearalenone-glucuronide 
(ZEN-GlcA) in urine after intra-gastric administration of ZEN (3 mg/kg bw) to pigs (n = 8). The mean 
ratio of the HRMS peak areas of ZEN-GlcA/13C18-ZEN + SD is shown. 
2.3.2. Broiler Chickens 
AFB1 and OTA were detected in plasma, as well as in excreta samples. No other relevant 
metabolites were found by LC-HRMS. The concentration (response)–time curves are shown in Figure 
10. OTA and AFB1 showed a second peak in the plasma concentration–time curve around 4 h p.a. 
This can be attributed to enterohepatic recirculation, which has previously been described for OTA 
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Figure 9. (A) Concentration–time curve f nivalenol (DON) in urine after intra-gastric
administration of DON (36 µg/kg bw) to pigs (n = 8). The mean + SD is shown (B) Concentration–time
curves of zearalenone (ZEN) in urine after intra-gastric administration of ZEN (3 mg/kg bw) to pigs
(n = 8). The mean + SD is shown. (C) The HRMS response–time curves of zearalenone-glucuronide
(ZEN-GlcA) in urine after intra-gastric administration of ZEN (3 mg/kg bw) to pigs (n = 8). The mean
ratio of the HRMS peak areas of ZEN-GlcA/13C18-ZEN + SD is shown.
2.3.2. Broiler Chickens
AFB1 and OTA were detected in plasma, as well as in excreta samples. No other relevant
metabolites were found by LC-HRMS. The concentration (response)–time curves are shown in Figure 10.
OTA and AFB1 showed a second peak in the plasma concentration–time curve around 4 h p.a. This can
be attributed to enterohepatic recirculation, which has previously been described for OTA [49,50].
The maximum concentration measured for AFB1 was 8.4 ng/mL and for OTA was 50 ng/mL, for both
toxins observed after 15 min. After administration of DON, only DON-sulfate was found in plasma
and excreta due to the high conversion rate of DON to DON-sulfate in broiler chickens, confirming
previous literature reports [9,16]. The maximum response was achieved after 30 min.
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Figure 10. (A) Conce tration–time curves of aflatoxi 1 ( FB1) and ochratoxin A (OTA), and HRMS
response–time curves of deoxynivalenol-sulfate (DON-S) in plasma after PO administration of
deoxynivalenol (DON, 0.5 mg/kg bw), AFB1 (2 mg/kg bw) and OTA (0.25 mg/kg bw) to broiler
chickens (n = 16). The mean + SD is shown for AFB1 and OTA and the mean ratio of the HRMS
peak areas of DON-S/13C15-DON + SD is shown. (B) Concentration–time curves of AFB1 and
OTA and HRMS response–time curves of DON-sulfate (DON-S) in excreta after PO administration
of DON (0.5 mg/kg bw), AFB1 (2 mg/kg bw) and OTA (0.25 mg/kg bw) to broiler chickens
(n = 16). The mean + SD is shown for AFB1 and OTA and the mean ratio of the HRMS peak areas of
DON-S/13C15-DON + SD is shown.
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2.4. Screening Study
Plasma samples from pigs and broiler chickens were obtained from the field and analyzed with the
presented method for the presence of mycotoxins in plasma. Two interesting samples are highlighted.
The first sample is a pig plasma sample from Belgium. This sample contained ZEN, TeA and DON
with respective concentrations of 1, 1.9 and 8.6 ng/mL. The chromatograms are shown in Figure 11.
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3. Conclusions
This paper describes a fully validated quantitative targeted LC/MS-MS method, and a qualitative
untargeted LC-HRMS approach to determine mycotoxins and their relevant metabolites in easily
obtainable biological matrices of pigs and broiler chickens. The methods were applied to plasma, urine,
feces and/or excreta samples that were obtained during in vivo toxicokinetic studies with DON and
ZEN in pigs, and with DON, AFB1 and OTA in broiler chickens and during a pilot field screening study
to monitor exposure to mycotoxins. These results show the successful applicability of the multi-method
to pig and broiler chicken samples, providing a proof-of-concept of the developed methods.
4. Materials and Methods
4.1. Chemicals, Products and Reagents
The analytical standards of ZEN, T2, HT2 toxin (HT2), OTA, AFB1, aflatoxin M1 (AFM1), FB2,
AOH, alternariol monomethyl ether (AME), TeA, DON, 3ADON, 15ADON, enniatin A (ENNA),
enniatin A1 (ENNA1), enniatin B1 (ENNB1), enniatin B (ENNB) and BEA were obtained from
Fermentek (Jerusalem, Israel). Zearalanone (ZAN), α-zearalenol (AZEL), β-zearalenol (BZEL),
α-zearalanol (AZAL) and β-zearalanol (BZAL) were purchased from Sigma-Aldrich (Bornem, Belgium).
De-epoxy-deoxynivalenol (DOM-1) was obtained from Biopure (Tulln, Austria). T-2 toxin-3α-glucoside
(T2G) was synthesized by the U.S. Department of Agriculture (USDA) as described [51,52]. Internal
standards (IS) of 13C15-DON, 13C24-T2, 13C18-ZEN, 13C20-OTA, 13C34-FB1 and 13C17-AFB1 were
purchased from Biopure. The internal standard 13C615N-TeA was synthesized according to the
method of Asam et al. [53], and 15N3-ENN B was synthesized according to the method of Hu and
Rychlik [54]. All standards were stored according to the recommendations of the supplier. Water,
methanol (MeOH), acetonitrile (ACN), ammonium formate, glacial acetic acid and formic acid for the
preparation of mobile phases were of LC-MS grade and were obtained from Biosolve (Valkenswaard,
The Netherlands). Acetone, ammonium formate, formic acid and ethyl acetate were of analytical
grade and were purchased from VWR (Leuven, Belgium). Millex®-LG filter units (0.2 µm), sodium
hydroxide (NaOH) pellets and hydrochloric acid (HCl) 37% fuming solution were obtained from
Merck (Overijse, Belgium). Ostro®-96 well plates were obtained from Waters (Milford, MA, USA).
HybridSPE®-phospholipid 30 mg/1 mL SPE tubes were purchased from Sigma-Aldrich. Merck Alcalit
pH indicator paper pH 0–14 was obtained from Novolab (Geraardsbergen, Belgium).
4.2. Preparation of Standard Solutions
Standard stock solutions (SS) for ZEN, AZAL, BZAL, AZEL, BZEL, ZAN, DON, T2, T2-G, HT2,
AFB1, AFM1, AOH, AME, ENNs, BEA and FB1 were prepared in ACN at 100 µg/mL. Standard
SS for OTA was prepared in ACN at 10 µg/mL. The standard SS of TeA was prepared in methanol
at 100 µg/mL. Following standards were purchased as solutions: 3ADON (100 µg/mL in ACN),
15ADON (100 µg/mL in ACN) and DOM-1 (50 µg/mL in ACN). A standard SS of 10 µg/mL in ACN
was prepared for DOM-1. All internal standards (IS) were obtained as solutions: 13C15-DON (25 µg/mL
in ACN), 13C24-T2 (25 µg/mL in ACN), 13C18-ZEN (25 µg/mL in ACN), 13C20-OTA (10 µg/mL in
ACN), 13C34-FB1 (25 µg/mL in ACN/water) and 13C17-AFB1 (0.5 µg/mL in ACN). Standard SS of
the synthesized internal standards were prepared at a concentration of 100 µg/mL in MeOH for
13C615N-TeA and 10 µg/mL in ACN for 15N3-ENN B. The SS were stored at ≤−15 ◦C.
A combined working solution of all analytical standards (WSmix, without IS) at a concentration of
1 µg/mL was prepared by transferring 10 µL of the stock solutions with a concentration of 100 µg/mL
and 100 µL of a 10 µg/mL solution of DOM-1 and OTA, followed by further dilution with ACN up
to a total volume of 1 mL. Serial dilutions of the WSmix were prepared, yielding concentrations of
100 ng/mL and 10 ng/mL. Individual working solutions of 1 µg/mL were made for all IS, except
for 13C17-AFB1 (100 ng/mL) and 15N3-ENN B (100 ng/mL). Next, a combined working solution of
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all IS (WSmix_IS) was prepared with a final concentration of 100 ng/mL for all components, except
13C17-AFB1 (10 ng/mL) and 15N3-ENN B (10 ng/mL). All working solutions were stored at ≤−15 ◦C.
4.3. Biological Samples
A toxicokinetic study was performed to demonstrate the applicability of the developed method.
Incurred plasma samples were obtained from 8 hybrid pigs (6 weeks of age, 9.94 ± 1.24 kg, ♂/♀4/4),
dosed with a single oral (intragastric) bolus of DON (36 µg/kg bodyweight (bw)) and ZEN (3 mg/kg
bw) after a fasting period of 12 h, and from 16 12 h-fasted broiler chickens (Ross 308, 3 weeks of
age, 1.05 ± 0.11 kg, ♂/♀5/11) administered AFB1 (2 mg/kg bw), DON (0.5 mg/kg bw) and OTA
(0.25 mg/kg bw). All mycotoxin doses were administered as a single oral bolus (acute exposure,
by gavage), and corresponded with doses previously used in toxicokinetic studies and studies to test
the efficacy of mycotoxin detoxifiers. For DON, this dose was in agreement with the EU legislation in
feed. The maximum guidance level in pig feed is set at 0.9 mg/kg DON [3]. Pigs of this age category
consume on average 40 g feed/kg bw/day. This resulted in the administration of 36 µg DON/kg
bw as described in [8]. For broiler chickens, the EU regulations set the maximum guidance level at
5 mg/kg feed [3]. Broilers (±1 kg bw) consume on average 100 g feed/kg bw/day. This resulted in the
administration of 0.5 mg DON/kg bw as described in [8].
For ZEN in pigs and AFB1 and OTA in broiler chickens, the administered doses were higher
than set by the EU legislation. These doses corresponded to the doses previously administered in
toxicokinetic studies and studies to determine the efficacy of mycotoxin detoxifiers [50]. These higher
doses were necessary to obtain sufficiently high plasma concentrations to evaluate the toxicokinetic
parameters of the toxins, as well as to demonstrate the efficacy of mycotoxin detoxifiers. Although
the doses were higher than the guidance levels, they did not evoke clinical toxicity after this single
administration. This was the case in the previously mentioned studies [50], as well as in the present
study. The most important read-out of this single oral bolus dosing in animals is the area under the
plasma concentration–time curve (AUC), which has to be high enough to be able to demonstrate a
statistical significant reduction in AUC when combined with the detoxifier. As the goal here was to
evaluate the use of the analytical methods in this type of studies, the same doses were used.
Blood was sampled before administration (0 min) and at 5, 10, 20, 30, 45, 60, 90, and 120 min, and 3,
4, 6, 8, 10, 12 and 24 h after administration of mycotoxins. Blood was collected via the vena jugularis
in EDTA tubes using a Venoject® system and centrifuged (2851× g, 10 min, 4 ◦C) to obtain plasma,
which was stored at ≤−15 ◦C until analysis. Urine was collected from male pigs using pediatric urine
collection bags as described by Gasthuys et al.[55]. Sampling was done at 4 intervals: 0–4 h, 4–8 h,
8–12 h and 12–24 h. Feces were collected every 2 h by rectal stimulation of the pigs. Excreta were
collected every 2 h by placing the broiler chickens in separate boxes for sampling. The animal trial was
approved by the ethical committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience
Engineering of Ghent University (EC2017/05) on 30 March 2017.
A multi-mycotoxin LC-MS/MS analysis of the pig and chicken feed (Primoris, Zwijnaarde,
Belgium) showed only low amounts of DON (respectively, 139 and 140 µg/kg) and ZEN (respectively,
12 and 20 µg/kg). The feed was conform the EU legislation since these amounts are below the guidance
values of the European commission [3]. Blank plasma, urine and feces samples were obtained from pigs
and broiler chickens on the mycotoxin control diet. The blank samples were used for the preparation
of matrix-matched calibration curves and quality control samples.
Besides the toxicokinetic studies, a preliminary screening study (n = 1 farm per animal species)
was performed to monitor the exposure of pigs and broiler chickens to mycotoxins and to demonstrate
the applicability of the developed method in the field. Therefore, farms with problems that might be
related to mycotoxins (e.g., postpartum problems, tail necrosis and refused feed intake) and where
mycotoxins were found in feed were selected. Blood of 10 pigs (5 sows and 5 piglets) and 10 broiler
chickens (2 weeks of age) was collected around 30 min after feeding. The blood was collected in EDTA
tubes and centrifuged (2851× g, 10 min, 4 ◦C) to obtain plasma. The animal trial was also approved by
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the ethical committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering
of Ghent University (EC2017/115) on 30 March 2017.
4.4. Sample Pre-Treatment
4.4.1. Pig Plasma
To 250 µL of plasma, 20 µL of a 100 ng/mL WSmix_IS were added, vortex mixed and set for
equilibration at room temperature for 5 min. Next, 750 µL of ACN with 0.1% formic acid of analytical
grade were added, followed by vortex mixing (10 s) and centrifugation (8,517× g, 10 min, 4 ◦C).
The total supernatant was collected and dried under a nitrogen (N2) stream at 40 ± 5 ◦C. The dried
supernatant was reconstituted in 250 µL of methanol/water (85/15; v/v), followed by vortex mixing.
The reconstituted sample was transferred into an autosampler vial and an aliquot (5 µL) was injected
onto the LC-MS/MS and LC-HRMS instrument.
4.4.2. Pig Urine
To two tubes (tube 1 and 2), each containing 500 µL of urine, were added 20 µL of a 100 ng/mL
WSmix_IS, followed by vortex mixing and equilibration at room temperature for 5 min. The pH was
determined by means of pH test strips and was adjusted to pH 8 in tube 1 and to pH 2 in tube 2, using
a 0.1 M NaOH solution and a 1 M HCl solution, respectively. This pH adjustment was necessary to
allow extraction of the different mycotoxins. At pH 8 most mycotoxins were extracted except for TeA,
AOH, AME and OTA that extracted best at pH 2.
Thereafter, 3 mL of ethyl acetate were added to each tube, followed by vortex mixing for 10 s
and rotating during 15 min on a horizontal roller shaker (Staffordshire, UK). Finally, the tubes were
centrifuged for 10 min at 3724× g and 4 ◦C. The organic phase of each tube was transferred to separate
polypropylene tube and evaporated to dryness using a gentle N2-stream at 40 ± 5 ◦C. The dried
extracts of tube 1 and 2 were reconstituted in 250 µL of MeOH/water (85/15; v/v) and vortex mixed.
The redissolved extracts of tube 1 and 2 were transferred to a separate autosampler vial and an aliquot
(5 µL) was injected onto the analytical instruments.
4.4.3. Pig Feces
Feces samples were first freeze dried for 48 h to eliminate variation due to different moisture
contents. Then, 20 µL of a 100 ng/mL WSmix_IS were added to two tubes (tube 1 and 2), each containing
250 mg of freeze-dried feces. The samples were vortex mixed during 10 s and equilibrated at room
temperature for 5 min. The extraction of TeA, OTA, AME and AOH was performed using tube 2,
with 5 mL of methanol/ethyl acetate/formic acid of analytical grade (75/24/1; v/v), whereas the
other mycotoxins were extracted using tube 1 with 5 mL of acetone. Both tubes were shaken for
40 min on an in-house made vertical rotator (75 rpm), followed by centrifugation (3724× g, 10 min,
4 ◦C). The supernatant of tube 1 was transferred onto a HybridSPE-phospholipid cartridge. The eluate
of tube 1 and the supernatant of tube 2 were evaporated until dryness using a gentle N2-stream at
40 ± 5 ◦C. The dried extracts were reconstituted in 250 µL of MeOH/water (85/15; v/v) and filtered
through a Millex®-LG 0.2 µm filter. The redissoved extracts of tube 1 and 2 were transferred to a
separate vial and an aliquot (5 µL) was injected onto the LC-MS/MS and the LC-HRMS instrument.
4.4.4. Broiler Chicken Plasma
First, 150 µL of chicken plasma was brought in a well of an Ostro® 96-well plate. Next, 15 µL
of a 100 ng/mL WSmix_IS were added, followed by a gentle up and down pipetting for mixing and
equilibration for 5 min at room temperature. Next, 450 µL of ACN containing 0.1% formic acid of
analytical were added. After gentle mixing, the Ostro® 96-well plate was placed under vacuum
(67.7 kPa) to allow the sample to pass through the plate. The eluate of each sample was transferred
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to a polypropylene tube, dried under a gentle N2-stream at 40 ± 5 ◦C and reconstituted in 150 µL of
MeOH/water (85/15; v/v). An aliquot of 5 µL was injected onto the analytical instruments.
4.4.5. Broiler Chicken Excreta
Excreta samples were first freeze dried for 48 h to eliminate variation due to different moisture
contents. The extraction of TEA, AME, OTA and AOH was performed in acidic medium (tube 1),
whereas the other mycotoxins were extracted without adjustment of the pH (tube 2). Hence, 250 mg
of freeze-dried chicken excreta were added to tube 1 and 2, followed by the addition of 20 µL of a
100 ng/mL WSmix_IS and equilibration for 5 min at room temperature. Next 1.5 mL of ACN was added
to both tubes, followed by adding 250 µL of a 1 M HCl solution to tube 1. The pH of the excreta
in tube 2 was not adjusted. The two tubes were vortex mixed and shaken for 15 min on a vertical
rotator, followed by centrifugation (3724× g, 10 min, 4 ◦C). The supernatants were transferred to
separate polypropylene tubes and dried under a N2-stream at 40 ± 5 ◦C. The dried extracts were
reconstituted in 250 µL of MeoH/water (85/15; v/v) and filtered through a Millex®-LG 0.2 µm filter.
Each sample was transferred to a separate vial. An aliquot of 5 µL was injected onto the LC-MS/MS
and LC-HRMS instruments.
4.5. Chromatography
The chromatographic systems consisted of an Acquity H-Class ultra-performance liquid
chromatograph (UPLC) coupled to a Xevo® TQ-S mass spectrometer and an Acquity I-Class
UPLC coupled to a Synapt® G2-Si high definition mass spectrometer (HDMS), all from Waters.
Chromatographic separation was achieved on an Acquity HSS T3 column (100 mm × 2.1 mm i.d.,
dp: 1.8 µm) and a VanGuard pre-column of the same type (5 mm × 2.1 mm i.d., dp: 1.8 µm),
both from Waters. The temperatures of the column oven and autosampler tray were set at 45 ◦C and
8 ◦C, respectively.
The chromatographic conditions were optimized for the different ionization modes, i.e., positive
and negative electro-spray ionization (ESI). The optimal chromatographic conditions for the ESI
positive mode were obtained with the mobile phases (MP) containing 10 mM ammonium formate,
0.3% formic acid in water (MP A), and 10 mM ammonium formate, 0.3% formic acid in methanol
(MP B), all of LC-MS grade. In ESI negative mode, the most suitable mobile phases consisted of 1%
acetic acid in water (MP C) and 1% acetic acid in acetonitrile (MP D), all of LC-MS grade. A gradient
elution program was run for each ionization mode separately. For ESI positive: 0–1.5 min, 95% A,
5% B; 1.5–3 min, linear gradient to 40% A; 3–5 min, 40% A, 60% B; 5.0–10 min, linear gradient to 20% A;
10–10.50 min, linear gradient to 1% A; 10.50–13.0 min, 1% A, 99% B; 13–14 min, linear gradient 95% A;
14.0–16.0 min, 95% A, 5% B. For ESI negative: 0–1.5 min, 95% C, 5% D; 1.5–3 min, linear gradient to
60% C; 3.0–4.0 min, 60% C, 40% D; 4.0–7.0 min, linear gradient to 40% C; 7.0–9.0 min, 40% C, 60% D;
9.0–9.5 min, linear gradient 95% C; 9.5–12.0 min, 95% C, 5% D. The flow rate was set at 300 µL/min.
The chromatographic parameters were the same for both the LC-MS/MS and LC-HRMS instruments.
4.6. Mass Spectrometry
Instrument parameters were optimized by syringe infusion of working solutions of 10 µg/mL of
each compound (flow rate 10 µL/min).
4.6.1. LC-MS/MS
The settings on the Xevo® TQ-S mass spectrometer were as follows: desolvation gas flow
rate: 800 L/h; desolvation temperature: 600 ◦C; cone gas flow rate: 150 L/h; source temperature:
150 ◦C. The capillary voltage was optimized at 3.2 kV for ESI positive and 3.0 kV for ESI negative
mode, respectively. Dwell times of 25 and 10 ms/transition were selected for each component
separately. The Xevo® TQ-S mass spectrometer was operated in the selected reaction monitoring (SRM)
mode. For every compound, the two most intense product ions were selected for quantification and
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qualification, respectively. In Table 3; Table 4, an overview is given of the compound specific MS/MS
parameters at the selected ionization mode (ESI negative and ESI positive, respectively).
4.6.2. LC-HRMS
Following instrument parameters were selected: desolvation gas flow: 800 L/h; desolvation
temperature: 600 ◦C; cone gas flow: 50 L/h; source temperature: 150 ◦C. The capillary voltage was
3.2 kV for ESI positive and and 3.0 kV for ESI negative. The HRMS acquisition was performed in
resolution mode using the MSE continuum scan function. The MSE data acquisition was optimal
for use in the Unify 1.8. software (Waters, Milford, MA, USA). The settings were as follows: low
mass, 50 dalton (Da); high mass, 1200 Da; scan time, 0.1 s; data format, continuum. The lock mass
solution consisted of leucine encephalin (200 pg/µL). The lock spray capillary voltage was 2.8 kV
for positive and 2.15 kV for the negative ionisation mode. The additional lock spray settings were
as follows: scan time, 0.1 s; interval, 30 s; scans to average, 3; mass window, 0.5 Da. The lock spray
was acquired during HRMS acquisition, but not corrected. The lock spray correction (m/z 556.276575;
m/z 554.26202) and data processing was performed using Unify 1.8 software (Waters, Milford, MA,
USA). Identification of analytes for which analytical standards were available was based on retention
time (target TR tolerance: 0.1 min) and mass (target mass tolerance: 10 ppm). Identification of phase I
and II metabolites for which no analytical standards existed was based on the found exact mass (target
mass tolerance: 10 ppm).
For every mycotoxin and some of their phase I and II metabolites, the accurate masses were
defined in the Unify 1.8 processing method, as shown in Table S1. The search for phase I and II
metabolites was performed using a pathway profiling approach. Additional adducts (e.g., Na+, NH4+,
CH3COO−, HCOO−) and the following transformations were added to the method: glucuronidation,
sulfation, oxidation, glutathione conjugations, glucosylations. After detection of a peak based on
the accurate mass by Unify 1.8, the given MS/MS spectrum was inspected to confirm the proposed
structure based on the present product ions.
4.7. Method Validation
The LC-MS/MS method was validated according to a protocol previously described by De Baere
et al. [35], using spiked blank plasma, urine and feces samples obtained from healthy, untreated
animals. The validation requirements are in compliance with the recommendations and guidelines
defined by the European and international Community [56–58]. Following parameters were evaluated:
linearity, within-day and between-day precision and accuracy, limit of quantification (LOQ), carry
over, specificity, extraction recovery and matrix effects.
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ZEN [M − H]− 317.1 175.0 130.8 15 25-30 8.50
ZAN [M − H]− 319.1 275.0 205.0 20 20-22 8.41
BZEL [M − H]− 319.2 275.0 301.0 20 20-22 6.87
BZAL [M − H]− 321.2 277.2 303.3 30 23-20 6.75
AZEL [M − H]− 319.2 275.0 301.0 20 20-22 7.51
AZAL [M − H]− 321.2 277.2 303.3 30 23-20 7.36
TeA [M − H]− 196.1 112.0 139.0 55 23-23 6.06
AOH [M − H]− 256.8 213.0 185.2 20 28-28 6.33
AME [M − H]− 271.1 256.0 228.0 48 24-30 8.38
[13C18]-zearalenone [M − H]− 335.3 185.1 169.1 15 28-40 8.50
[13C615N]-tenuazonic acid [M − H]− 202.9 113.1 141.9 40 23-20 6.06
Note: m/z = mass-to-charge ratio; (a-b): collision energy for the quantifier (a) and qualifier ion (b), respectively.












DON [M + H]+ 297.0 249.1 203.4 20 9-14 4.36
DOM1 [M + H]+ 281.0 215.0 233.0 30 12-12 4.70
3/15-ADON [M + H]+ 339.2 213.1 230.9 25 12-8 5.02
T2 [M + NH4]+ 484.0 215.2 304.8 26 18-15 8.24
HT2 [M + NH4]+ 442.0 263.0 215.1 20 10-10 7.01
T2-G [M + NH4]+ 646.0 245.0 215.3 35 20-22 7.20
AFB1 [M + H]+ 313.0 285.1 241.1 35 23-34 5.63
AFM1 [M + H[+ 328.9 272.9 229.0 30 20-35 5.18
OTA [M + H]+ 404.0 238.9 220.8 35 20-32 9.23
ENN A1 [M + H]+ 668.2 210.1 227.9 80 20-20 12.96
ENN A [M + Na]+ 704.5 350.1 232.2 35 48-48 13.12
ENN B [M + H]+ 640.1 213.8 527.2 80 22-21 12.69
ENN B1 [M + NH4]+ 671.5 196.2 214.3 30 28-28 12.84
BEA [M + H]+ 784.1 244.0 262.1 80 25-30 12.81
FB2 [M + H]+ 706.10 318.2 336.2 60 35-42 10.07
[13C15]-Deoxynivalenol [M + H]+ 312.0 263.0 245.0 20 10-10 4.37
[13C17]-Aflatoxin B1 [M + H]+ 330.10 255.1 301.0 20 35-28 5.63
[13C20]-Ochratoxin A [M + H]+ 424.0 250.0 377.1 20 25-15 9.23
[13C24]-T2-toxin [M + NH4]+ 508.40 229.1 198.2 25 20-20 8.24
[13C34]-Fumonisin B1 [M + H]+ 756.50 356.2 374.3 15 40-35 9.67
[15N3]-Enniatin B [M + H]+ 643.30 197.1 215.30 80 18-18 12.69
Note: m/z = mass-to-charge ratio; (a-b): collision energy for the quantifier (a) and qualifier ion (b), respectively.
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4.7.1. Linearity
Linearity was assessed by preparing three matrix-matched calibration curves over a concentration
range of 1–200 ng/mL or 1–200 ng/g. Ten concentrations were included: 0, 1, 2, 4, 5, 10, 30, 50,
100 and 200 ng/mL or ng/g. The correlation coefficients (r) and the goodness-of-fit coefficients (g)
were calculated and acceptance criteria were set, respectively, at ≥0.99 and ≤20% [59].
4.7.2. Precision and Accuracy
Within-day precision and accuracy were evaluated by analyzing six blank samples spiked at low
(LOQ), medium (10 ng/mL or ng/g) and high (100 ng/mL or ng/g) concentration levels. Between-day
precision and accuracy were determined by analyzing in threefold three quality control samples
spiked at low (LOQ), medium (10 ng/mL or ng/g) and high (100 ng/mL or ng/g) concentration level
on three different days. The acceptance criteria for within-day and between-day accuracy were as
follows: −50% to +20%, −30% to +10% and −20 to +10% for concentrations of ≤1 ng/mL or ng/g,
1–10 ng/mL or ng/g and ≥10 ng/mL or ng/g, respectively. For the within-day precision, the relative
standard deviation (RSD%) had to be lower than the maximum relative standard deviation (RSDmax),
which was <25%, and <15% for concentrations ≥1 to <10 ng/mL or ng/g and ≥10 to <100 ng/mL or
ng/g, respectively [58]. For the between-day precision, the RSD% had to be lower than the RSDmax,
which was defined by the Horwitz equation: RSDmax = 2(1–0.5 log Concentration(g/mL)). The RSDmax was
22.6%, 32% and 45% for the respective concentrations of 100 ng/mL, 10 ng/mL and 1 ng/mL [56,57].
4.7.3. Limit of Quantification (LOQ)
The LOQ was the lowest concentration of the analyte for which the method was validated with
an acceptable accuracy and precision according to the guidelines described above. The LOQ was also
the lowest concentration of the calibration curves. The LOQ was determined by analyzing different
concentrations spiked in six-fold on the same day.
4.7.4. Carry Over
Carry over was assessed by analyzing a mixture of MeOH/water (85/15; v/v) directly after the
highest calibrator (200 ng/mL or ng/g). The concentration of mycotoxins in this mixture had to be
below a signal-to-noise ratio of 3/1.
4.7.5. Specificity
The specificity of the method was evaluated with respect to interference of endogenous
components. Hence, a blank sample was analyzed. The signal of the eventual interference at the
elution zone of the analytes of interest should be below the signal-to-noise ratio of 3/1.
4.7.6. Extraction Recovery and Matrix Effects
The extraction recovery and matrix effects of the method were calculated according to the method
of Matuszewski et al. [60] Therefore, three types of samples were prepared. The first samples were
matrix-matched and prepared by spiking blank samples before extraction (=Spiked). The second
samples consisted of matrix-matched blank samples that were spiked after extraction (=SpikedExtract).
The third samples were prepared using standard solutions (=Standard). All samples were spiked at
10 ng/mL or 10 ng/g and were made in triplicate. The peak areas of these samples were compared to
calculate the recovery of the extraction step (RE) and the signal suppression/enhancement (SSE) due
to matrix effects.
SSE = 100 × (Area SpikedExtract/Area Standard)
RE = 100 × (Area Spiked/Area SpikedExtract)
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